Head-to-head evidence
Elacestrant vs Vepdegestrant
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline
Elacestrant
Marketed by Stemline Therapeutics, Inc.
NCT03778931 · Phase 3 · completed
This was a large randomized trial comparing elacestrant with active standard-of-care treatment, but it was open-label rather than double-blind. The primary progression-free survival endpoints, assessed by blinded imaging review, were statistically significantly better with elacestrant in both ESR1-mutant and all participants, but the lack of participant and investigator blinding limits the strength of the evidence.
Next expected readout: November 2026 · NCT06691035 (registry estimate)
Vepdegestrant
Marketed by Rigel Pharmaceuticals and partners
NCT04072952 · Phase 1/2 · completed
The study enrolled 219 participants but was non-randomized, open-label, and lacked a control group; its primary outcomes focused mainly on dose-limiting toxicities, adverse events, and laboratory abnormalities rather than a controlled efficacy comparison. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2026 · NCT05573555 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Elacestrant's landscape · Vepdegestrant's landscape